Le valproate de sodium: Une drogue hyperammonemiante Étude chez l'épileptique et chez le volontaire sain

[1]  A. Marini,et al.  Sodium Valproate‐induced hyperammonemia without clinical hepatic dysfunction , 1982, Neurology.

[2]  E. Jones,et al.  HEPATIC ENCEPHALOPATHY AND THE γ-AMINOBUTYRIC-ACID NEUROTRANSMITTER SYSTEM , 1982, The Lancet.

[3]  B. Wilder,et al.  Central actions of valproic acid in man and in experimental models of epilepsy. , 1981, Life sciences.

[4]  H. Gastaut,et al.  A Case of Fatal Toxic Hepatitis: Recommendations for the Administration of Sodium Valproate , 1981, Epilepsia.

[5]  H. Swick,et al.  Valproic acid and secondary hyperammonemia , 1981, Neurology.

[6]  R. Allen,et al.  Hyperammonemia with valproic acid therapy. , 1981, The Journal of pediatrics.

[7]  G. Grimber,et al.  Letter to the Editor: A Mechanism for Valproate-Induced Hyperammonemia , 1981, Pediatric Research.

[8]  L. Wendt,et al.  Dipropylacetate and aminoaciduria , 1980, Journal of the Neurological Sciences.

[9]  G. Millward-Sadler,et al.  ACUTE LIVER DISEASE ASSOCIATED WITH SODIUM VALPROATE , 1980, The Lancet.

[10]  J. Iles,et al.  Ammonia: assessment of its action on postsynaptic inhibition as a cause of convulsions. , 1980, Brain : a journal of neurology.

[11]  J. Jaeken,et al.  VALPROATE, HYPERAMMONÆMIA, AND HYPERGLYCINÆMIA , 1980, The Lancet.

[12]  R. Allen,et al.  SECONDARY HYPERAMMONÆMIA: A POSSIBLE MECHANISM FOR VALPROATE ENCEPHALOPATHY , 1980, The Lancet.

[13]  J. Koch-weser,et al.  Drug therapy: Valproic acid. , 1980, The New England journal of medicine.

[14]  J. Sackellares,et al.  Stupor Following Administration of Valproic Acid to Patients Receiving Other Antiepileptic Drugs , 1979, Epilepsia.

[15]  W. Koella,et al.  Central actions of valproate sodium , 1979, The Journal of pharmacy and pharmacology.

[16]  G. Bergey,et al.  Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons , 1979, Brain Research.

[17]  E. C. Hwang,et al.  Effect of valproic acid on serotonin metabolism , 1979, Neuropharmacology.

[18]  Gerald E. Slater,et al.  Sodium Valproate Increases Potassium Conductance in Aplysia Neurons , 1978, Epilepsia.

[19]  B. Meldrum,et al.  Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate. , 1977, European journal of pharmacology.

[20]  B. Meldrum,et al.  Effects of Anticonvulsant Drugs on the Cerebral Enzymes Metabolizing GABA , 1975, Epilepsia.

[21]  P. Mandel,et al.  Effect of sodium n-dipropylacetate on audiogenic seizures and brain -aminobutyric acid level. , 1973, Biochemical pharmacology.

[22]  P. Mandel,et al.  EFFECTS OF DI‐n‐PROPYLACETATE, AN ANTICONVULSIVE COMPOUND, ON GABA METABOLISM 1 , 1969, Journal of neurochemistry.

[23]  J. E. Bradley,et al.  Uptake of ammonia by muscle; its implications in ammoniagenic coma. , 1955, The New England journal of medicine.

[24]  M. Moore.  Book ReviewWhen Minds Go Wrong. , 1955 .

[25]  L. Rumbach,et al.  L'hyperammoniémie isolée. Une conséquence fréquente des traitements par la valproate de sodium. , 1981 .

[26]  J. Schlienger,et al.  An Automated Microassay for Blood Ammonia , 1979, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.